Showing 8691-8700 of 20413 results for "".
Modern Approaches to Chronic Spontaneous Urticaria Care
https://reachmd.com/programs/on-the-frontlines-of-chronic-spontaneous-urticaria/a-practical-guide-to-chronic-spontaneous-urticaria/56726/Chronic spontaneous urticaria (CSU) can be difficult to control, particularly for patients whose symptoms persist despite antihistamine therapy. As treatment options continue to expand, clinicians must understand how biomarkers, guideline-based treatment algorithms, and newly available therapies canEnsitrelvir and Nirmatrelvir: Comparing Viral Clearance in COVID-19
https://reachmd.com/programs/clinicians-roundtable/ensitrelvir-nirmatrelvir--viral-clearance-covid-19/48839/The GLP-1 Stress Test: Where the Liquid Facelift Hits the Wall
https://reachmd.com/ma-issues-index/jan-feb-2026-issue/the-glp-1-stress-test-where-the-liquid-facelift-hits-the-wall/54421/Evaluating Post-CDK4/6 Therapy in PIK3CA-Mutated Metastatic Breast Cancer
https://reachmd.com/programs/project-oncology/post-cdk46-therapy-pik3ca-mutated-metastatic-breast-cancer/36167/Real-world evidence is critical for guiding post-CDK4/6 treatment decisions in patients with PIK3CA-mutated metastatic breast cancer. That’s why a recent study presented at the 2025 San Antonio Breast Cancer Symposium analyzed treatment patterns, real-world outcomes, and resistance mechanisms followClinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
https://reachmd.com/programs/project-oncology/tovorafenib-clinical-stability-pediatric-low-grade-glioma/37195/What if clinical stability in pediatric low-grade glioma could be maintained after treatment ends? Emerging data from the phase 2 FIREFLY-1 trial suggest that tovorafenib may offer durable off-therapy disease control, even in the presence of radiographic changes. With a 53% objective response rate,Building Trust in Psoriasis Care: Tools for Better Patient Conversations
https://reachmd.com/programs/frontlines-psoriasis/building-trust-in-psoriasis-care-tools-for-better-patient-conversations/32441/What you say to a patient with newly diagnosed psoriasis can shape their entire care journey. That’s why Dr. Ben Ehst joins Ryan Quigley to share real-world strategies for building trust from the very first conversation. He offers guidance on simplifying the science, addressing common misconceptionsUnderstanding Who Joined COVID-19 Vaccine Trials and Why
https://reachmd.com/programs/clinicians-roundtable/understanding-who-joined-covid-19-vaccine-trials-and-why/36416/Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
https://reachmd.com/programs/neurofrontiers/clemastine-fumarate-and-progressive-ms-a-closer-look-at-unexpected-risks-and-mechanisms/32825/Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
https://reachmd.com/programs/clinicians-roundtable/beyond-disease-control-pros-with-odronextamab-in-rr-follicular-lymphoma/37208/In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some caThe Role of the Complement System in Kidney Diseases
https://reachmd.com/programs/cme/the-role-of-the-complement-system-in-kidney-diseases/35706/The Role of the Complement System in Kidney Diseases